Dr. Susan Eckerle

Pic of Dr. Susan Eckerle

LiSyM-Cancer Program Management – Scientific Databases and Visualization – Heidelberg Institute of Theoretical Studies (HITS) gGmbH, Heidelberg

pm Program and Communication Management

Role in LiSyM-Cancer

  • Project and Communication Manager in LiSyM-Cancer
  • Support the Director, Data Management, and Leadership Team
  • Facilitation of cross-network consortial collaboration for the successful achievement of individual network and consortium milestones
  • Scientific Project Manager for the C-TIP-HCC network

Expertise

  • Coordination of research alliances and network management
  • Cooperation and communication with partners and stakeholders
  • Contract and financial management
  • Applications and reporting
  • Development of study documents
  • Ethics, data protection, and compliance in studies

Degrees

  • 2008, PhD:
    • Molecular Pathology of Human Lymphoma and Immune Cells
    • Senckenbergisches Institute for Pathology, Medical Center of the Johann Wolfgang-Goethe University, Frankfurt/Main
    • Institute for Cell Biology (Tumor Research), University Medical Center Essen-Duisburg
  • Diploma in Human Biology, Philipps University Marburg

Professional Experience

  • Since 2022, Program Management LiSyM-Cancer, HITS gGmbH Heidelberg
  • Since 2021, Scientific Project Coordination C-TIP-HCC, University Medical Center Mannheim
  • 2019 – 2020, Study Coordinator, BGU Frankfurt/Main
  • 2019, Qualification EU-Fundraising, emcra GmbH, Berlin
  • 2017 – 2018, Clinical Scientific Study Coordinator for GPOH, GBA, BMBF, Foundation funded research projects, Department of Pediatric Hematology and Oncology, University Medical Center Mainz
  • 2013 – 2017, Study Manager, Interdisciplinary Collaborative Study on Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS-study, http://www.cvss-studie.de/, DFG-funded), University Medical Center Mainz
  • 2009 – 2013, Medical Affairs Manager for biologics for the treatment of rheumatological and orphan diseases, Pharmaceutical Industry